Exposing Pump and Dumps - All my own opinions / not financial advice
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
You start with good news then bring in the non-event stuff. The fact that he is delaying is because he is boring everyone to death with the Chris Reckor stuff which Buyerstrike already ruined
There will not be an uplist
1) They don't meet stockholders equity
2) PPS lookback doesn't meet minimum
3) Net tangible assets doesn't meet it
1a) They need to raise equity but can't bc of the Fife ratchet
2a) Need some good news to get it up. We will see
3a) Again, need to raise equity
Patterson is a paid shill who wrote in May of 2020 that Leronlimab has no statistically significant improvement in COVID. Just have to read the entire thing. Patterson was also paid 500k shares for his pumping
Dr Been runs a gym, he's hardly a respected doctor
Jacob is a scam artist that was from Quest that got promoted at CYDY.
Dr Drew said COVID wasn't a threat
This is a giant cesspool of filth that even Hellen Keller could see/hear if she were alive today.
Oh can't forget the
Why was biotech intelligence piece pulled?
https://biotechintelligence.blogspot.com/2020/09/interviews-with-cytodyn-nader.html?m=1
NASDAQ UPLIST REJECTED
There u go
Nader paying himself more, more staff, more trials, more legal obligations, more inducement charges, they will have a larger negative Net Income this Q than last Q. The uplist is doomed as well as this stock. Leronlimab is a joke. Rantes = CCL5 and even Dr Bruce Patterson very recently wrote a paper that has a horrific p-value associated with CCL5. I suggest you all read it!
Even adjusting for all the CF in 1Q: Stockholders’ equity based on only public filings (10K) -$2.5mm + 7.8mm warrants, + 10.8mm warrant/stock options exercised + 9.5mm conversion of debt to equity = $25.7mm stockholders equity. Well that’s great but the 10Q is going to be ugly. Last Q they lost $35mm from operations and this Q they will have at least 2mm of inducement expenses and finance charges. So you’re at a $37mm loss which gets them to -11mm 1Q Stockholders’ equity + any change in fair value of derivatives, which won’t be more than $16mm.
Well its obvious it didn't get approval based on share price, NTA, and Stockholders' equity requirements. Does anyone actually think they had a chance?
$17mm NEEDED TO UPLIST
Before you type out harsh responses, or hot air, please take a second to read as I am welcome to any actual responses that contradict below:
According to Nasdaq rules, stockholders equity needs to be $5mm page 10 *** since it is below $4 [url][/url][tag]https://listingcenter.nasdaq.com/assets/initialguide.pdf[/tag]
They 10K has Q end of -$2.5mm in stockholders equity
They raise 7.8mm in warrants, 10.8mm from warrants/stock options, and $9.537.500 from conversion of debt to equity. This leaves them at 25.657mm in stockholders equity
Now going back to the 10K, the last Q had -27.819.494 operating loss and -57.611.207 in net income. Add back the 22.5mm from the Fife legal settlement and you're at ~35mm net loss for the Q
Now, let's assume operating loss increases at the same percentage as last Q (given lots of trials, R&D etc). That get's you to -$35mm in operating losses
Now let's add deduct 700k from finance charges (the most recent Fife PIPE and there are more but let's assume they had some offsetting ones as well somehow) and -500 in inducement interest (see 10K) and you get to roughly $37mm of neg net income
$25.567mm stock holders equity
Less $37mm neg net income
= ~-11mm stockholders equity
Now in order to get to $5mm+ stock holders equity they need to raise at least $16mm in equity before month's end
Scooter,
1) Can you tell me what primary endpoint was? [url][/url][tag]https://clinicaltrials.gov/ct2/show/NCT04343651[/tag]
2) Then can you tell me if they met it? [url][/url][tag]https://www.marketwatch.com/press-release/cytodyn-announces-clinically-significant-top-line-results-from-its-phase-2-trial-in-mild-to-moderate-covid-19-patients-2020-08-11-9184163?mod=mw_quote_news[/tag]
I'll help you out
1) 14 day was primary
2) No, they did not meet it
10K due today!
1) Looks like uplist is gone
2) Stock has been very weak since they reported results, which indicated they didn't meet their primary endpoint. Which means, per the FDA, due to multiplicity and alpha spend, the secondary endpoints cannot be statsig. Every biotech investor knows this, which is why they are pressing their shrots.
3) Nader knows he will not meet any endpoint in moderate/severe so he is pumping the EUA. However, everyone knows since Leronlimab missed its primary endpoint, per the FDA, due to multiplicity and alpha spend, the secondary endpoints cannot be statsig; therefore, EUA will never happen.
4) Here comes $0.20
It doesn't matter. Read up on multiplicity and alpha spend. This is why you cannot have statsig secondary end points w/o having statsig primary end points. From a statistical standpoint, on which is what the FDA relies, this was a FAIL and the drug would be rejected regardless of secondary endpoints. That is why there will be no emergency use approval
Per the FDA "SEs are not sufficient to support efficacy in the absence of an effect on one or more primary endpoints
Leronlimab did not meet primary endpoint
Why do you all completely gloss over this FACT
He gets it
This PR shows that the emperor truly has no clothes.
The soon to come exaggerated tout video forward looking statements with tons of disclaimers will certainly be one to watch with popcorn. I hope we see a little pop in the stock so I can add!
Cannot be stat sig if primary endpoint fails You understand this right? You cannot have a stat sig secondary end point if the primary end point failed. The primary endpoint failed or it would have been released today instead of a random secondary subset. This is the end
Fox and MSNBC are reporters just like WSJ, which trashed Nadder. Medical Journals? Which one Nature.com. Please refer me to NIH, NEJM, JAMA, etc you know real medical publications
Please enlighten us on how Leronlimab, which has been around forever without any partnerships or success has a "big lead."
Please, try to enlighten us without referencing anything published by a paid promoter (BP, Scott, Emerginggrowth.com, Proactive investors, etc.)
Thanks
Because they can't prove short sellers wrong w/o bald faced lies. The last DUMP was followed by a PUMP last week talking about German shares hitting $8 (not Euros), which never happened (peaked at 4.6EUR), only to fall bc of a "short attack", which never happened (only 60k shares traded).
More lies - Samsung deal. Remember the Samsung deal? That subsequently collapsed?
Remember the Mexico trail? NEVER HAPPENED cut it because they didn't want to run it anymore?
The bottom line is....Google Pump & Dump and read
Confirmed. Q&A is a bad SNL skit
Most Ridiculous Q&A I Have Ever Heard
I have at a HF for 15yrs, listen to upwards near 50 calls a Q and I have never, ever, heard anything quite as obnoxious as this call and subsequent Q&A. There are no real questions, Nader gave no real data, outside of mixed results (nothing to see!) and efficacious vs placebo on vents but didn't provide any data. Not to mention "slapped around by regulators" lolololol and cannot provide 50 patient data.
This doctor saying the studies are more efficacious than anything he has ever seen. Funny thing is, outside of SAE, there is no data, so what on earth is he talking about and how is he a docotor?
He hasn't said anything. He said on his primary btw he said beat placebo on day 3 vs. Day 0 on some parameters...Type A so they are starting all over again? LOLOLOLOLOLOLOL
He said it can take up to six weeks. You better believe they will file a shelf and raise capital before turning over that card. Hard to imagine they aren't in possession of MNPI while raising the capital. This may be what takes The Nader and BP down.
Yes they announced safety but not efficacy. They voted to sell more shares and the endpoints in this trial are stupid.
Don't forget that BP is paid by the company and none of his research has been peer reviewed! Nothing to see here!
You’re reallllyyyyy reaching. This is a biotech PR for a data readout. If there were anything whatsoever positive to pump/gloat they would be doing it. The sheer fact that they can only pump safety means everything else was garbage. This is why it’s getting faded
Bc Nader just admitted no efficacy. Could only scrub the data for safety
So now it’s a safety trial? Where’s the efficacy data? Lololol this will get faded. What a joke even the fraudulent data massagers like Nader and Patterson couldn’t scrub their way to anything positive outside of safety! C’mon open your eyes
They better be getting to work! I mean they have two dozen different indications for one product! WOW!
What can't Leronlimab cure?!?!?!? Could it possible cure bagholders' sorrows? Find out on the next Nader's Dreamcatcher pump and dump proactive shareholder video!
I actually added short on the fake volume at the end of the day ;)
Unblinded will = no efficacy. I have my sources ;)
Have fun bag holders
If this doesn't show how manipulated this stock is..... Heavy volume = down... Light volume past noon every tick up. Then rallies on light volume to green. LOL. This one gonna be a fun one allll the way down
The equity standard still requires 90 straight trading days with PPS > $4. Not sure your point.
Why do you keep deflecting from the original point JustDaFacts was making.
Page 8 footnote:
"Currently traded companies qualifying solely under the Market Value Standard must meet the $75 million Market Value of Listed
Securities and the $4 bid price requirement for 90 consecutive trading days before applying"
On 7/13 CYDY closed at $3.7
Can anyone get to the $80mm in total assets requirement too?
If it dips? It’s down 30% in Germany right now. They’ve been working on BLA for HIV indication for years without any success and now got a rejection letter. Why on earth would any rational human being think they can get approval for COVID when they’ve been working on HIV for years without any success.
Doesn’t matter, leronlimab got blocked for HIV indication. No shot it gets approval for covid.
*CYTODYN GETS REFUSAL TO FILE LETTER FOR LERONLIMAB COMBINATION
How can you expect to get approval for other indications if blocked for HIV?!
Bye bye bag holders
That's 100000% unsubstantiated. You can't make that claim on anecdotes even if BP and the Nader say these aren't anecdotes...They're anecdotes as far as the science community and FDA are concerned.